Trials / Completed
CompletedNCT02194023
Clinical Effects of Two New Chlorhexidine Digluconate Formulations: 0.12% and 0.03%.
Inhibition of de Novo Plaque Formation and Side Effects of Two New Mouthrinse Formulations: 0.12% and 0.03% Chlorhexidine Digluconate, Respectively, in a 4-day Non-brushing Model. A Triple-blind, Randomized Clinical Trial.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- Universitat Internacional de Catalunya · Academic / Other
- Sex
- All
- Age
- 18 Years – 30 Years
- Healthy volunteers
- Accepted
Summary
In the current study we tested the hypothesis that new 0.05% Cetylpyridinium chloride (CPC) mouthrinse formulations containing 0.12% or 0.03% chlorhexidine digluconate (CHX): 1) yield similar or better clinical results regarding the inhibition of de novo plaque growth compared to those achieved with an already marketed 0.12% CHX mouthrinse (Perio-Aid Treatment without alcohol. Dentaid, Spain), 2) reduce the side effects caused by the marketed 0.12% CHX formula and 3) that these mouthrinses have no negative microbiological effects, and they control total bacterial loads.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo: PCB | Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes. |
| DRUG | 0.12%NF | Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes. |
| DRUG | 0.03%NF | Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes. |
| DRUG | PAT | Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes. |
Timeline
- Start date
- 2011-09-01
- Primary completion
- 2013-07-01
- Completion
- 2013-07-01
- First posted
- 2014-07-18
- Last updated
- 2014-07-18
Locations
1 site across 1 country: Spain
Source: ClinicalTrials.gov record NCT02194023. Inclusion in this directory is not an endorsement.